Curative Biotechnology Inc. (CUBT)
Market Closed
11 Aug, 20:00
OTC PINK OTC PINK Primary $
1. 00
-0.12
-11.1111%
$
7.98M Market Cap
- P/E Ratio
- Div Yield
118 Volume
0 Eps
$ 1.12
Previous Close Want to track CUBT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CUBT closed today lower at $1, a decrease of -11.1111% from yesterday's close, completing a monthly increase of 32.9416% or $0.25. Over the past 12 months, CUBT stock gained 20,102.0202%.
CUBT is not paying dividends to its shareholders.
The last earnings report, released on Aug 05, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Curative Biotechnology Inc. has completed 6 stock splits, with the recent split occurring on Mar 23, 2026.
The company's stock is traded on one exchange.
Curative Biotechnology Inc. (CUBT) FAQ
What is the stock price today?
The current price is $1.00.
On which exchange is it traded?
Curative Biotechnology Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is CUBT.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 7.98M.
Has Curative Biotechnology Inc. ever had a stock split?
Curative Biotechnology Inc. had 6 splits and the recent split was on Mar 23, 2026.
Curative Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | I. Richard Garr CEO | OTC PINK Exchange | 23128N306 CUSIP |
| US Country | 4 Employees | - Last Dividend | 23 Mar 2026 Last Split | 20 Sep 2017 IPO Date |
Overview
Curative Biotechnology, Inc. is a Palm Beach Gardens, Florida-based development-stage biopharmaceutical company committed to the development, licensing, and commercialization of innovative pharmaceutical products and medical devices. The company has a strategic focus on addressing unmet medical needs in various therapeutic areas, including infectious diseases, oncology, and degenerative eye diseases. Through its collaborative and in-house development efforts, Curative Biotechnology aims to bring forward novel treatments that can significantly improve patient outcomes and quality of life.
Products and Services
Curative Biotechnology, Inc. has an exciting pipeline of product candidates targeting various disease states:
- Metformin Reformulation: Aimed at treating intermediate dry macular degeneration and geographic atrophy, this reformulated version of Metformin represents an innovative approach to slowing the progression of these degenerative eye diseases.
- IMT504: A novel immune therapy designed for the treatment of late-stage rabies. This investigational product highlights the company's commitment to addressing critical needs in infectious diseases. Additionally, Curative Biotechnology has entered into a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. for the further development of IMT504 for late-stage rabies and as a potential COVID-19 vaccine.
- CUBT906: This fully humanized CD56 monoclonal antibody is engineered to carry a pyrrolobenzodiazepine dimer directly to tumor sites. By doing so, CUBT906 aims to kill cancer cells by inhibiting tumor growth and preventing the migration of tumor cells, showcasing Curative Biotechnology's innovative approach to oncology.
Contact Information
Address: 3801 PGA Blvd Suite 600
Phone: 561-907-8990
Website: https://curativebiotech.com
